Tucatinib in patients with locally advanced or metastatic HER2-positive breast cancer who received at least two prior anti-HER2 treatment regimens: Study design of the non-interventional study TRACE in Germany and Austria

N. Harbeck , R. Bartsch , V. Müller , M. Balic , D. Egle , E. Schumacher-Wulf , M. Angerer , A. Nusch , C. Uleer , M. Welslau , J. Radosa , D. Wrobel , R. de Buhr , M. Glasstetter , J. Hanselmann , C. Hogrefe , N. Marschner ,K. Gratzke , A. Welt